Epic Sciences

No Cell Left Behind

CTC Detection and Characterization Platform

The Epic Sciences CTC detection and characterization platform has the potential to empower precision medicine with one, simple blood draw. It not only enables enumeration of CTCs, but also has the unique ability to evaluate protein biomarker expression and subcellular localization when used with our 1) 4 or 5-color immunofluorescence assays, 2) gene amplifications, deletions or rearrangements by DNA FISH and 3) genomic aberrations via mutation or copy number variation (CNV) analysis via next-generation sequencing (NGS).  Our assay development team is also available to generate custom assays for your biomarker of interest. If you are interested in a custom assay please contact us at info@epicsciences.com

The Epic Sciences platform provides a thorough view of disease heterogeneity by enabling CTC enumeration, biomarker characterization and downstream genomic capabilities.

CTC-DETECT-CHARACT_2x.png

Epic Sciences has developed numerous assays, which are being used to test more than 10,000 patient blood samples from clinical trial sites located in North America, Europe and Asia. These protein, FISH and genomic assays are designed to measure protein abnormalities in CTCs many different cancer types, with feasibility shown in more than a dozen to date.

CTC Detection and Characterization Tools

Enumeration

CTC enumeration on the Epic Sciences platform consists of:

CTC-ENUMERATION-SEQUENCE_2x.png

  1. Slide prep: Upon receipt of patient blood sample, whole blood is lysed and nucleated cells are deposited on up to 12 microscope slides that are frozen at -80 ºC until analysis.
  2. Cell staining and scanning: Slides are immunofluorescently stained and scanned by Epic’s rapid fluorescent scanning method, which images each nucleated cell.
  3. CTC identification and biomarker analysis: A digital pathology algorithm, which includes protein expression and morphology, differentiates candidate CTCs from surrounding white blood cells (WBCs). CTCs are confirmed and classified into one of the following categories (1) Traditional CTCs, (2) CTC clusters, (3) CK(-) CTCs and (4) Apoptotic CTCs (see CTC basics to review these different classes of CTCs).

Protein Biomarker Assays

Epic Sciences’ CTC protein biomarker analysis consists of:

  1. Slide prep: Upon receipt of a patient blood sample, whole blood is lysed and nucleated cells are deposited on up to 12 microscope slides that are frozen at -80 ºC until analysis.
  2. Cell staining and scanning: Slides are immunofluorescently stained and scanned by Epic Sciences’ rapid fluorescent scanning method, which images each nucleated cell.
  3. CTC identification and biomarker analysis: A digital pathology algorithm, which includes protein expression and morphology, differentiates candidate CTCs from surrounding white blood cells (WBCs). CTCs are confirmed and classified into one of the following categories (1) Traditional CTCs, (2) CTC clusters, (3) CK(-) CTCs and (4) Apoptotic CTCs (see CTC basics to review these different classes of CTCs).

PROTEIN-BIOMARKER-ASSAYS_2x.png

The open 4th and 5th channel can be integrated into our base assay for CTC identification and protein biomarker characterization. These are representative images (10x) of individual CLCs detected by our N-terminal Androgen Receptor (AR) assay. Blue = DAPI, red = Cytokeratin, green = CD45, white = N-terminal AR. 

Biomarker expression data can be extracted and quantitated on each individual CTC. Below is an example of biomarker analysis that looks at androgen receptor (AR) expression on cell line cells.  PC3s (AR negative) and LnCAPs (AR positive) were spiked into blood and analyzed by the Epic platform for AR expression. Each individual dot on the plot represents the AR expression of an individual CTC.

Epic Sciences has developed numerous assays, which are being used to test more than 10,000 patient blood samples from clinical trial sites located in North America, Europe and Asia. These protein, FISH and genomic assays are designed to measure protein abnormalities in CTCs for 12 different cancer types.